HomeCompareAYLA vs GBDC

AYLA vs GBDC: Dividend Comparison 2026

AYLA yields 374.60% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AYLA wins by $7084.73M in total portfolio value
10 years
AYLA
AYLA
● Live price
374.60%
Share price
$0.53
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7105.58M
Annual income
$4,658,993,972.92
Full AYLA calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — AYLA vs GBDC

📍 AYLA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAYLAGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AYLA + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AYLA pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AYLA
Annual income on $10K today (after 15% tax)
$31,841.17/yr
After 10yr DRIP, annual income (after tax)
$3,960,144,876.98/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, AYLA beats the other by $3,946,161,753.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AYLA + GBDC for your $10,000?

AYLA: 50%GBDC: 50%
100% GBDC50/50100% AYLA
Portfolio after 10yr
$3563.21M
Annual income
$2,337,722,353.38/yr
Blended yield
65.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

AYLA
Analyst Ratings
6
Buy
2
Hold
1
Sell
Consensus: Buy
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AYLA buys
0
GBDC buys
0
No recent congressional trades found for AYLA or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAYLAGBDC
Forward yield374.60%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$7105.58M$20.85M
Annual income after 10y$4,658,993,972.92$16,450,733.83
Total dividends collected$6876.29M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: AYLA vs GBDC ($10,000, DRIP)

YearAYLA PortfolioAYLA Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$48,160$37,460.20$12,492$1,791.70+$35.7KAYLA
2$220,138$168,606.60$16,527$3,160.58+$203.6KAYLA
3$955,821$720,273.70$23,588$5,904.90+$932.2KAYLA
4$3,945,504$2,922,775.63$37,141$11,901.65+$3.91MAYLA
5$15,497,234$11,275,544.08$66,205$26,463.38+$15.43MAYLA
6$57,972,988$41,390,948.05$137,452$66,612.65+$57.84MAYLA
7$206,739,282$144,708,184.88$342,372$195,298.53+$206.40MAYLA
8$703,499,231$482,288,199.06$1,053,292$686,954.33+$702.45MAYLA
9$2,286,525,626$1,533,781,448.26$4,111,439$2,984,416.95+$2282.41MAYLA
10$7,105,576,392$4,658,993,972.92$20,849,974$16,450,733.83+$7084.73MAYLA

AYLA vs GBDC: Complete Analysis 2026

AYLAStock

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Full AYLA Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this AYLA vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AYLA vs SCHDAYLA vs JEPIAYLA vs OAYLA vs KOAYLA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.